Lenalidomide Capsule
Product Images NDC 60505-4532

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 60505-4532). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1.jpg (Figure1)

A Kaplan-Meier survival curve showing progression-free survival over months for three treatment groups: Rd Continuous, Rd18, and MPT. The y-axis represents survival probability (%), and the x-axis represents progression-free survival time in months. The chart includes hazard ratios with 95% confidence intervals comparing the groups, a logrank p-value, and a table of subjects at risk over time for each group.*

FDA Label Image

Figure2.jpg (Figure2)

A Kaplan-Meier survival probability chart depicting overall survival over months for three treatment groups: Rd Continuous (blue solid line), Rd18 (green dashed line), and MPT (red dash-dotted line). The y-axis shows survival probability (%) and the x-axis shows overall survival in months up to 72. Below the plot is a table showing the number of subjects at risk over time for each group. Hazard ratios comparing groups with 95% confidence intervals are also included on the graph.*

FDA Label Image

Figure3.jpg (Figure3)

A Kaplan-Meier curve graph depicting the proportion of subjects over time to progression in months, comparing Lenalidomide/Dex treatment (blue line) versus Placebo/Dex treatment (black line). The graph includes a hazard ratio (HR) with 95% confidence interval and a log-rank p-value, illustrating statistical differences in progression times between the two groups.*

FDA Label Image

Figure4.jpg (Figure4)

A Kaplan-Meier survival curve graph depicting the proportion of subjects over time to progression in months. The graph compares two groups: Lenalidomide/Dex (blue line) and Placebo/Dex (black line). The hazard ratio (HR) with 95% confidence interval and a log-rank p-value are displayed on the chart.*

FDA Label Image

Figure5.jpg (Figure5)

A Kaplan-Meier survival plot illustrating progression-free survival comparison between Lenalidomide and placebo over approximately 108 months. The graph shows higher survival probability for Lenalidomide (blue solid line) versus placebo (red dashed line). Below the plot, a table lists the number of subjects at risk over time for each group. The figure includes hazard ratio, confidence intervals, median survival times, and event counts for both groups.*

FDA Label Image

Figure6.jpg (Figure6)

A Kaplan-Meier survival curve chart showing progression-free survival probability over time in months. The chart compares Lenalidomide (blue solid line) and placebo (red dashed line) groups. The X-axis represents progression-free survival in months, and the Y-axis shows survival probability from 0 to 1. A table below shows the number of subjects at risk at various time points for both groups. Text on the chart indicates hazard ratio (HR) with confidence interval, median progression-free survival times for Lenalidomide and placebo, and event counts with percentages.*

FDA Label Image

Figure7.jpg (Figure7)

A Kaplan-Meier curve illustrating progression-free survival over 48 months comparing two groups: Rituximab plus Lenalidomide (blue line) and Rituximab plus Placebo (red line). The vertical axis shows survival probability, and the horizontal axis shows time in months. The chart includes a table of subjects at risk over time and hazard ratio with confidence interval and p-value.*

FDA Label Image

Lenalidomide10mg (Lenalidomide10mg)

Lenalidomide 10 mg capsules label from Apotex Corp. The label indicates the package contains 28 capsules. It includes storage instructions, a warning about potential human birth defects, and manufacturer details, including Apotex Inc. in Toronto, Ontario, and Apotex Corp. in Weston, Florida. The label has a barcode and the statement Rx Only.*

FDA Label Image

Lenalidomide15mg (Lenalidomide15mg)

Packaging label for Lenalidomide capsules, 15 mg strength, by Apotex Corp. The label indicates 21 capsules per bottle and includes storage instructions (20°-25°C, 15°-30°C excursions allowed). There is a boxed warning noting potential human birth defects, along with dispensing instructions for pharmacists to provide the Medication Guide to patients. The label shows manufacturing information for Apotex Inc. and Apotex Corp.*

FDA Label Image

Lenalidomide25mg (Lenalidomide25mg)

Label for Lenalidomide Capsules 25 mg by Apotex Corp, showing package size of 21 capsules. The label includes a warning about potential human birth defects, storage instructions (20°C to 25°C), and dispensing guidelines. Manufactured by Apotex Inc., Canada, and for Apotex Corp., Florida. Includes barcode and prescription designation (Rx only).*

FDA Label Image

Lenalidomide5mg (Lenalidomide5mg)

Lenalidomide Capsules 5 mg in a package containing 28 capsules. Label indicates storage instructions, dosage form as capsules for oral use, and a warning about potential human birth defects. Labeler is Apotex Corp. with manufacturing locations in Toronto, Ontario, and Weston, Florida. Includes barcode and directions to dispense enclosed medication guide to patients.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of Lenalidomide, showing its molecular framework including an amino group, ketone groups, and a lactam ring system.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.